{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:04:24Z","timestamp":1786997064595,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019886","name":"Legend Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.soncn.2023.151505","type":"journal-article","created":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:57:52Z","timestamp":1695542272000},"page":"151505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Nursing Care Throughout the Chimeric Antigen Receptor T-Cell Therapy Process for Multiple Myeloma"],"prefix":"10.1016","volume":"39","author":[{"given":"Mary","family":"Steinbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Zitella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Florendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Riccobono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"DiFilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10297","key":"10.1016\/j.soncn.2023.151505_bib0001","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.soncn.2023.151505_bib0002","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2023.151505_bib0003","series-title":"Center for Biologics Evaluation and Research. CARVYKTI Approval Letter","author":"Bryan","year":"2022"},{"key":"10.1016\/j.soncn.2023.151505_bib0004","series-title":"Center for Biologics Evaluation and Research. ABECMA Approval Letter","author":"Malarkey","year":"2021"},{"issue":"3","key":"10.1016\/j.soncn.2023.151505_bib0005","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.soncn.2023.151505_bib0006","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.soncn.2023.151505_bib0007","doi-asserted-by":"crossref","unstructured":"Martin T, Usmani SZ, Berdeja JG, et al. Updated Results from CARTITUDE-1: Phase 1b\/2 Study of Ciltacabtagene Autoleucel, a B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients with Relapsed\/Refractory Multiple Myeloma. Presented at the 63rd American Society of Hematology Annual Meeting and Exposition. Presentation #549. 2021.","DOI":"10.1016\/j.htct.2021.10.460"},{"key":"10.1016\/j.soncn.2023.151505_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.620312","article-title":"Toxicities of chimeric antigen receptor T cell therapy in multiple myeloma: an overview of experience from clinical trials, pathophysiology, and management strategies","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.soncn.2023.151505_bib0009","unstructured":"Prescribing Information. CARVYKTI. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/CARVYKTI-pi.pdf. Last updated February 2022. Accessed March 2, 2022."},{"key":"10.1016\/j.soncn.2023.151505_bib0010","unstructured":"Prescribing Information. ABECMA. https:\/\/packageinserts.bms.com\/pi\/pi_abecma.pdf. Last updated March 2021. Accessed July 11, 2022."},{"key":"10.1016\/j.soncn.2023.151505_bib0011","unstructured":"National Institutes of Health, US National Library of Medicine. clinicaltrials.gov\/ct2\/show\/NCT04196491. Accessed: August 5, 2022."},{"key":"10.1016\/j.soncn.2023.151505_bib0012","unstructured":"National Institutes of Health, US National Library of Medicine. clinicaltrials.gov\/ct2\/show\/NCT03601078. Accessed: August 5, 2022."},{"key":"10.1016\/j.soncn.2023.151505_bib0013","unstructured":"National Institutes of Health, US National Library of Medicine. clinicaltrials.gov\/ct2\/show\/NCT04133636. Accessed: August 18, 2022."},{"key":"10.1016\/j.soncn.2023.151505_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric antigen receptor T-cell therapies: barriers and solutions to access","author":"Mikhael","year":"2022","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.soncn.2023.151505_bib0015","first-page":"27","article-title":"Management across settings: an ambulatory and community perspective for patients undergoing CAR T-cell therapy in multiple care settings","volume":"23","author":"Beaupierre","year":"2019","journal-title":"Clin J Oncol Nurs"},{"issue":"6","key":"10.1016\/j.soncn.2023.151505_bib0016","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.bbmt.2018.02.018","article-title":"Building a CAR garage: preparing for the delivery of commercial CAR T cell products at Memorial Sloan Kettering Cancer Center","volume":"24","author":"Perica","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 3","key":"10.1016\/j.soncn.2023.151505_bib0017","first-page":"29","article-title":"Educating multidisciplinary care teams, patients, and caregivers on CAR T-cell therapy","volume":"10","author":"Beaupierre","year":"2019","journal-title":"J Adv Pract Oncol"},{"issue":"8","key":"10.1016\/j.soncn.2023.151505_bib0018","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00277-022-04881-0","article-title":"Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma","volume":"101","author":"Ring","year":"2022","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.soncn.2023.151505_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002056","article-title":"Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia","volume":"9","author":"Myers","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.soncn.2023.151505_bib0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA: a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"issue":"1","key":"10.1016\/j.soncn.2023.151505_bib0021","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.soncn.2023.151505_bib0022","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.soncn.2023.151505_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.soncn.2023.151505_bib0024","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","article-title":"A guide to manufacturing CAR T cell therapies","volume":"53","author":"Vormittag","year":"2018","journal-title":"Curr Opin Biotechnol"},{"issue":"18","key":"10.1016\/j.soncn.2023.151505_bib0025","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.soncn.2023.151505_bib0026","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.soncn.2023.151505_bib0027","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1097\/HS9.0000000000000018","article-title":"Chimeric antigen receptor-T cell therapy: practical considerations for implementation in Europe","volume":"2","author":"Buechner","year":"2018","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.soncn.2023.151505_bib0028","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.soncn.2023.151505_bib0029","unstructured":"Anderson LD Jr, Shah N, Jagannath S, et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma: updated results from KarMMa. 2021. Presented at the International Myeloma Workshop 2021 [presentation #OAB27]. Available at: https:\/\/www.myelomasociety.org\/wp-content\/uploads\/2021\/09\/anderson-1.pdf."},{"key":"10.1016\/j.soncn.2023.151505_bib0030","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soncn.2023.151505_bib0031","doi-asserted-by":"crossref","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"issue":"6","key":"10.1016\/j.soncn.2023.151505_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy-a brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.soncn.2023.151505_bib0033","first-page":"13","article-title":"Associated toxicities: assessment and management related to CAR T-cell therapy","volume":"23","author":"Anderson","year":"2019","journal-title":"Clin J Oncol Nurs"},{"issue":"12","key":"10.1016\/j.soncn.2023.151505_bib0034","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.soncn.2023.151505_bib0035","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","article-title":"Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma","volume":"2","author":"van de Donk","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1016\/j.soncn.2023.151505_bib0036","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1634\/theoncologist.2019-0395","article-title":"Axicabtagene ciloleucel, an anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: practical implications for the community oncologist","volume":"25","author":"Jacobson","year":"2020","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.soncn.2023.151505_bib0037","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.soncn.2023.151505_bib0038","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1182\/bloodadvances.2019000790","article-title":"Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults","volume":"3","author":"Derman","year":"2019","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.soncn.2023.151505_bib0039","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.soncn.2023.151505_bib0040","first-page":"20","article-title":"Building a program: implications for infrastructure, nursing education, and training for CAR T-cell therapy","volume":"23","author":"Taylor","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.soncn.2023.151505_bib0041","unstructured":"Cancer and Your Finances. Leukemia & Lymphoma Society. https:\/\/www.lls.org\/booklet\/cancer-and-your-finances. Updated 2022. Accessed 9\/14\/22."},{"issue":"3","key":"10.1016\/j.soncn.2023.151505_bib0042","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s44228-022-00004-8","article-title":"The EBMT immune effector cell nursing guidelines on CAR-T therapy: a framework for patient care and managing common toxicities","volume":"4","author":"Ellard","year":"2022","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.soncn.2023.151505_bib0043","series-title":"Standards for Immune Effector Cells, First Edition 1.1","year":"2018"},{"issue":"4","key":"10.1016\/j.soncn.2023.151505_bib0044","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.soncn.2023.151505_bib0045","unstructured":"MD Anderson Cancer Center. CARTOX app version 2.5. \/\/apps.apple.com\/us\/app\/cartox\/id1464005828 \/play.google.com\/store\/apps\/details?id=org.mdanderson.cartox&hl=en_US&gl=US."},{"key":"10.1016\/j.soncn.2023.151505_bib0046","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.soncn.2023.151505_bib0047","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1369\/00221554221079579","article-title":"Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-targeting multiple myeloma therapy","volume":"70","author":"Marella","year":"2022","journal-title":"J Histochem Cytochem"},{"issue":"2","key":"10.1016\/j.soncn.2023.151505_bib0048","first-page":"42","article-title":"Adult Survivorship: Considerations Following CAR T-Cell Therapy","volume":"23","author":"Buitrago","year":"2019","journal-title":"Clin J Oncol Nurs"},{"issue":"10","key":"10.1016\/j.soncn.2023.151505_bib0049","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.soncn.2023.151505_bib0050","series-title":"Long Term Follow-Up After Administration of Human Gene Therapy Products. Guidance for Industry","year":"2020"},{"issue":"1","key":"10.1016\/j.soncn.2023.151505_bib0051","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000796","article-title":"Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer","volume":"8","author":"Annapragada","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.soncn.2023.151505_bib0052","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.soncn.2023.151505_bib0053","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.soncn.2013.02.005","article-title":"Oncology nurse navigators and the continuum of cancer care","volume":"29","author":"McMullen","year":"2013","journal-title":"Semin Oncol Nurs"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208123001547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208123001547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:41:16Z","timestamp":1760082076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208123001547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0749208123001547"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2023.151505","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nursing Care Throughout the Chimeric Antigen Receptor T-Cell Therapy Process for Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2023.151505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151505"}}